PortfoliosLab logoPortfoliosLab logo
ISIN
US1101221083
CUSIP
110122108
IPO Date
Jan 1, 1972

Highlights

Market Cap
$111.78B
Enterprise Value
$148.97B
EPS (TTM)
$3.57
PE Ratio
15.34
PEG Ratio
0.88
Total Revenue (TTM)
$48.48B
Gross Profit (TTM)
$33.33B
EBITDA (TTM)
$13.34B
Year Range
$42.52 - $62.89
Target Price
$62.00
ROA (TTM)
8.41%
ROE (TTM)
36.25%

Share Price Chart


Loading charts...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

BMY Performance Chart

Bristol-Myers Squibb Company (BMY) is up 3.7% since the beginning of the year. At $55 per share, BMY is trading 13.0% below its 52-week high of $63. Investors who bought $1,000 worth of BMY shares 5 years ago would now be looking at an investment worth $1,025.


Loading charts...

S&P 500 Index

Returns By Period

Bristol-Myers Squibb Company (BMY) has returned 3.67% so far this year and 22.56% over the past 12 months. Over the last ten years, BMY has returned 0.91% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.


Bristol-Myers Squibb Company

1D
1.30%
1M
-8.01%
YTD
3.67%
6M
2.30%
1Y
22.56%
3Y*
-1.14%
5Y*
0.49%
10Y*
0.91%

Benchmark (S&P 500 Index)

1D
-0.37%
1M
-0.01%
YTD
9.16%
6M
8.64%
1Y
25.22%
3Y*
19.78%
5Y*
11.99%
10Y*
13.88%
*Multi-year figures are annualized to reflect compound growth (CAGR)

BMY Monthly Returns History

Based on dividend-adjusted daily data since Jun 1, 1972, BMY's average daily return is +0.05%, while the average monthly return is +0.96%. At this rate, an investment would double in approximately 6.0 years.

Historically, 56% of months were positive and 44% were negative. The best month was Oct 1974 with a return of +42.1%, while the worst month was Apr 2002 at -28.4%. The longest winning streak lasted 10 consecutive months, and the longest losing streak was 8 months.

On a daily basis, BMY closed higher 48% of trading days. The best single day was Oct 21, 1987 with a return of +15.9%, while the worst single day was Apr 19, 2000 at -22.5%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20263.26%13.30%-2.76%0.93%-5.63%-4.34%3.67%
20255.38%1.14%2.30%-16.80%-3.82%-4.12%-5.20%8.94%-4.41%3.55%6.79%9.63%0.11%
2024-3.65%3.85%6.86%-18.03%-6.49%1.07%16.26%5.03%3.58%9.00%6.19%-4.49%15.81%
20231.77%-5.08%0.51%-2.87%-3.49%-0.76%-1.89%-0.87%-5.86%-10.32%-4.17%3.91%-26.14%
20224.99%5.83%7.13%3.07%0.24%2.76%-4.18%-8.63%5.46%9.80%3.63%-10.38%18.98%
2021-0.97%-0.16%3.74%-1.12%5.29%1.67%2.32%-1.49%-10.78%-1.30%-8.17%16.26%2.88%

Benchmark Metrics

Bristol-Myers Squibb Company has an annualized alpha of 4.96%, beta of 0.79, and R2 of 0.27 versus S&P 500 Index. Calculated based on daily prices since June 01, 1972.

  • This stock participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (85.51%) than losses (80.44%) - typical of diversified or defensive assets.
  • R2 of 0.27 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
4.96%
Beta
0.79
0.27
Upside Capture
85.51%
Downside Capture
80.44%

Return for Risk

Risk / Return Rank

BMY ranks 68 for risk / return — better than 68% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.


BMY Risk / Return Rank: 6868
Overall Rank
BMY Sharpe Ratio Rank: 6868
Sharpe Ratio Rank
BMY Sortino Ratio Rank: 6464
Sortino Ratio Rank
BMY Omega Ratio Rank: 6161
Omega Ratio Rank
BMY Calmar Ratio Rank: 7474
Calmar Ratio Rank
BMY Martin Ratio Rank: 7373
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for Bristol-Myers Squibb Company (BMY) and compare them to S&P 500 Index.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


BMYBenchmarkDifference
Sharpe ratioReturn per unit of total volatility

-1.19

Sortino ratioReturn per unit of downside risk

-1.35

Omega ratioGain probability vs. loss probability

1.16

1.37

-0.20

Calmar ratioReturn relative to maximum drawdown

1.81

2.78

-0.98

Martin ratioReturn relative to average drawdown

4.13

12.44

-8.31

Dividends

Dividend History

Bristol-Myers Squibb Company provided a 4.57% dividend yield over the last twelve months, with an annual payout of $2.50 per share. The company has been increasing its dividends for 4 consecutive years.


2.00%2.50%3.00%3.50%4.00%4.50%$0.00$0.50$1.00$1.50$2.00$2.5020152016201720182019202020212022202320242025
Dividends
Dividend Yield
PeriodTTM20252024202320222021202020192018201720162015
Dividend$2.50$2.48$2.40$2.28$2.16$1.47$2.29$1.64$1.60$1.56$1.14$1.49

Dividend yield

4.57%4.60%4.24%4.44%3.00%2.36%3.69%2.55%3.08%2.55%1.95%2.17%

Monthly Dividends

The table displays the monthly dividend distributions for Bristol-Myers Squibb Company. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2026$0.63$0.00$0.00$0.63$0.00$0.00$1.26
2025$0.62$0.00$0.00$0.62$0.00$0.00$0.62$0.00$0.00$0.62$0.00$0.00$2.48
2024$0.60$0.00$0.00$0.60$0.00$0.00$0.60$0.00$0.00$0.60$0.00$0.00$2.40
2023$0.57$0.00$0.00$0.57$0.00$0.00$0.57$0.00$0.00$0.57$0.00$0.00$2.28
2022$0.54$0.00$0.54$0.00$0.00$0.54$0.00$0.00$0.00$0.54$0.00$0.00$2.16
2021$0.00$0.00$0.49$0.00$0.00$0.00$0.49$0.00$0.49$0.00$0.00$0.00$1.47

Dividend Yield & Payout


Dividend Yield

Bristol-Myers Squibb Company has a dividend yield of 4.57%, which is quite average when compared to the overall market.

Payout Ratio

Bristol-Myers Squibb Company has a payout ratio of 69.69%, which is quite average when compared to the overall market. This suggests that Bristol-Myers Squibb Company strikes a balance between reinvesting profits for growth and paying dividends to shareholders.

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading charts...

Worst Drawdowns

The table below displays the maximum drawdowns of the Bristol-Myers Squibb Company. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Bristol-Myers Squibb Company was 72.03%, occurring on Jul 24, 2002. Recovery took 2726 trading sessions.

The current Bristol-Myers Squibb Company drawdown is 21.28%.


Related event

Drawdown

Fall

Recovery

Underwater

Dot-com crash2000–2002
-72.03%Jul 2002
2y 8mo10y 10mo
13y 6moOct 1999 - May 2013
1974 bear market1974
-56.31%Oct 1974
2y 1mo1y 1mo
3y 3moAug 1972 - Nov 1975
2024 bear market2024
-47.67%Jul 2024
1y 7mo
3y 6moDec 2022 - now
2019 bear market2019
-39.30%Jul 2019
3y 7d1y 10mo
4y 10moJul 2016 - May 2021
1993 bear market1993
-38.47%Aug 1993
1y 7mo2y 1mo
3y 8moJan 1992 - Oct 1995

Drawdown Indicators


BMYBenchmarkDifference

Max Drawdown

Largest peak-to-trough decline

-72.03%

-56.78%

-15.25%

Max Drawdown (1Y)

Largest decline over 1 year

-12.53%

-9.10%

-3.43%

Max Drawdown (3Y)

Largest decline over 3 years

-36.02%

-18.90%

-17.12%

Max Drawdown (5Y)

Largest decline over 5 years

-47.67%

-25.43%

-22.24%

Max Drawdown (10Y)

Largest decline over 10 years

-47.67%

-33.92%

-13.75%

Current Drawdown

Current decline from peak

-21.28%

-1.80%

-19.48%

Average Drawdown

Average peak-to-trough decline

-22.38%

-10.71%

-11.67%

Ulcer Index

Depth and duration of drawdowns from previous peaks

5.48%

2.03%

+3.45%

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading charts...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Bristol-Myers Squibb Company over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Bristol-Myers Squibb Company is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PE Ratio

The chart displays the Price-to-Earnings (P/E) ratio for BMY, comparing it with other companies in the Drug Manufacturers - General industry. Currently, BMY has a P/E ratio of 15.3. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.

PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for BMY compared to other companies in the Drug Manufacturers - General industry. BMY currently has a PEG ratio of 0.9. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for BMY relative to other companies in the Drug Manufacturers - General industry. Currently, BMY has a P/S ratio of 2.3. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for BMY in comparison with other companies in the Drug Manufacturers - General industry. Currently, BMY has a P/B value of 5.6. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
Portfolio Analyzer

Build a portfolio with BMY

Add Bristol-Myers Squibb Company to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Analyzer with BMY